US 12,071,428 B2
Indazole compounds as kinase inhibitors
Robert L. Hudkins, Virginia Beach, VA (US); and Daniel C. Bensen, Carlsbad, CA (US)
Assigned to TYRA BIOSCIENCES, INC., Carlsbad, CA (US)
Filed by TYRA BIOSCIENCES, INC., Carlsbad, CA (US)
Filed on Feb. 22, 2024, as Appl. No. 18/584,440.
Application 18/584,440 is a continuation of application No. 18/259,422, previously published as PCT/US2021/065679, filed on Dec. 30, 2021.
Claims priority of provisional application 63/216,879, filed on Jun. 30, 2021.
Claims priority of provisional application 63/132,031, filed on Dec. 30, 2020.
Prior Publication US 2024/0208941 A1, Jun. 27, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01); A61P 35/00 (2006.01); C07D 417/14 (2006.01); C07D 471/10 (2006.01); C07D 487/10 (2006.01); C07D 495/10 (2006.01)
CPC C07D 401/14 (2013.01) [A61P 35/00 (2018.01); C07D 417/14 (2013.01); C07D 471/10 (2013.01); C07D 487/10 (2013.01); C07D 495/10 (2013.01)] 19 Claims
 
1. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:

OG Complex Work Unit Chemistry